PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.35%
Negative revenue growth while CVE stands at 1.87%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-31.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-108.89%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-108.89%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-104.03%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-104.13%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-104.05%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.85%
Share reduction while CVE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.02%
Reduced diluted shares while CVE is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
6.13%
Dividend growth under 50% of CVE's 28.33%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-3.44%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-17.89%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
179.63%
10Y revenue/share CAGR above 1.5x CVE's 63.51%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-60.37%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
25.85%
Positive 3Y CAGR while CVE is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
-69.62%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
59.63%
Positive OCF/share growth while CVE is negative. John Neff might see a comparative advantage in operational cash viability.
142.47%
3Y OCF/share CAGR at 50-75% of CVE's 205.99%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-100.55%
Negative 10Y net income/share CAGR while CVE is at 170.88%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-101.73%
Negative 5Y net income/share CAGR while CVE is 114.75%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
98.59%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-65.42%
Negative equity/share CAGR over 10 years while CVE stands at 22.13%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-41.48%
Negative 5Y equity/share growth while CVE is at 16.14%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
7.14%
3Y equity/share CAGR at 50-75% of CVE's 12.35%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
-90.36%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-71.46%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
18.03%
3Y dividend/share CAGR at 50-75% of CVE's 24.33%. Martin Whitman might see a weaker short-term approach to distributing cash.
-20.58%
Firm’s AR is declining while CVE shows 15.77%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.98%
Positive BV/share change while CVE is negative. John Neff sees a clear edge over a competitor losing equity.
0.24%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-95.62%
We cut SG&A while CVE invests at 76.39%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.